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Implantation of biodegradable wafers near the brain surgery site to deliver anti-cancer agents
which target residual tumor cells by bypassing the blood-brain barrier has been a promising
method for brain tumor treatment. However, further improvement in the prognosis is still
necessary. We herein present novel materials and device technologies for drug delivery to
brain tumors, i.e., a flexible, sticky, and biodegradable drug-loaded patch integrated with
wireless electronics for controlled intracranial drug delivery through mild-thermic actuation.
The flexible and bifacially-designed sticky/hydrophobic device allows conformal adhesion on
the brain surgery site and provides spatially-controlled and temporarily-extended drug
delivery to brain tumors while minimizing unintended drug leakage to the cerebrospinal fluid.
Biodegradation of the entire device minimizes potential neurological side-effects. Application
of the device to the mouse model confirms tumor volume suppression and improved survival
rate. Demonstration in a large animal model (canine model) exhibited its potential for human
application.
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Treatment of cancers in organs with special blood barrierssuch as brain, peritoneum, and oculus has always beenchallenging. Especially, treatment of malignant brain
tumors (e.g., glioblastoma; GBM) is extremely difficult1, because
tumor cells survive through surgical resection and radiation
therapy2,3, causing tumor recurrence. Conventional che-
motherapies through the intravenous delivery are oftentimes
unsuccesful since the blood–brain barrier blocks delivery of drugs
to brain tumors4. Several researches have improved controlled
and targeted drug delivery to brain tumors5–7. For example, the
biodegradable polymeric wafer8,9 (Gliadel wafer, Arbor Phar-
maceuticals, USA) implanted near the brain surgery site locally
delivers drugs to remaining brain tumors and exhibits meaningful
improvement. However, further advances in the treatment effi-
cacy are still necessary.
The requirements of the device for the controlled intracranial
drug delivery to brain tumors are as follows. The penetration10 of
the released drugs into brain tissues should be high for treatment
of infiltrated tumor cells. Local drug delivery to brain tumors
without unwanted release to cerebrospinal fluid (CSF) is impor-
tant11. Mechanical mismatch of rigid implantable devices from
brain tissues may cause neurological disorders, and thereby soft
electronic devices are preferred for intracranial implants12–14.
Devices with the capability of complete bioresorption can be a
good solution to prevent side effects of chronic implants15–18.
Long-term sustained drug delivery is helpful for cancer treat-
ment19,20. Toward accomplishment of these challenging goals
altogether, a novel soft biodegradable electronic device that can
actuate drug diffusion wirelessly and disappears after a desired
period of time17,21–23 in the brain15,16 is needed.
Here, we report materials and device technologies for a flexible,
sticky, and biodegradable wireless electronic device integrated
with a bifacially designed polymer drug reservoir, which is called
as a bioresorbable electronic patch (BEP). The BEP, together with
an associated mild-thermic actuation protocol, provides long
drug diffusion length and drug delivery duration. The flexibility
of the oxidized starch (OST)-based patch and its hydrophilic/
hydrophobic bifacial design allow conformal adhesion to the
target brain tissue24,25 and enable local and sustained drug
delivery, while reducing unintended drug release to CSF. Fully
bioresorbable and soft nature of the BEP minimizes potential
neurological side effects of rigid intracranial implants26. Wireless
mild-thermic actuation by the bioresorbable heater with the
alternating magnetic field enhances the penetration depth of
delivered drugs. The synergetic effect on brain tumor treatment
by integration of all these material and device components is
confirmed in mouse subcutaneous and canine brain GBM models
in vivo.
Results
Overview of materials and devices. The integrated device, BEP,
has a bifacial structure that is composed of a hydrophilic drug-
loaded OST film and a hydrophobic poly(lactic acid) (PLA)
encapsulation film (Fig. 1a). Magnesium-based ultrathin electro-
nic devices, which work as a wireless heater for mild-thermic drug
delivery actuation and a wireless temperature sensor for con-
trolled mild-thermic actuation, are embedded in these thin films
(Fig. 1b, left). All material elements of the BEP are bioresorbable,
and all biodegradation products are materials existing in the
human body27–30 (Fig. 1b, right). The detailed device fabrication
process is described in Supplementary Fig. 1. The BEP was
packaged (Fig. 1c), sterilized before implantation (Fig. 1d), and
applied to animal models for drug delivery to GBM (Fig. 1e, f).
Figure 1e shows the application process of the BEP in a canine
GBM model during the craniotomy (Fig. 1e, left) and lamination
of the BEP on the surgical site (Fig. 1e, right). The flexible and
sticky design of the BEP facilitates its conformal adhesion to the
curved brain cavity surface (Fig. 1f). The strong adhesion of
the hydrophilic OST bottom drug reservoir is due to the imine
conjugation (Fig. 1a, right). These conformal and strong adhesion
improves the efficiency of the drug delivery. Meanwhile, the
hydrophobic PLA top encapsulation reduces undesirable drug
delivery to CSF. The imine conjugation also helps long-term
sustained drug delivery. Then, an alternating radio frequency
(RF) magnetic field (220 kHz, 360A; Easyheat, Ambrell, USA) is
applied to actuate the heater in the BEP wirelessly, which releases
drugs from the reservoir, accelerates the intercellular drug
diffusion, and enhances the drug penetration depth (Fig. 1f).
The alternating RF magnetic field allows long-distance wireless
energy transfer through tissues31, which activates the mild-
thermic actuation to promote drug diffusion to microscopic
residual tumors invaded in normal brain tissues32.
Local drug delivery and biocompatibility. We first designed
materials for the BEP. It should conformally adhere to the curved
brain surface for local drug delivery, for facile heat transfer during
mild-thermic actuation, and for prolonged drug delivery duration
by minimizing unwanted drug leakage to CSF. This could be
achieved by using OST which is synthesized by oxidization of
starch (Supplementary Fig. 2). It provides strong imine con-
jugation to both brain tissues and drug molecules (e.g., doxor-
ubicin; DOX) (Fig. 2a, green), and thus enables good adhesion
and sustained drug release. The flexible drug-loaded patch was
made by mixing OST with DOX in PBS and dried under the
humid condition (Supplementary Fig. 3). DOX was used as a
major antitumor agent in this study because of its outstanding
therapeutic effect and easy visualization using fluorescence. The
maximum DOX loading amount that we have observed was
6.831 mg per one BEP since the DOX is highly miscible to the
OST. The total amount of DOX can be increased further by using
multiple BEPs. Further optimization to increase the drug loading
amount should be done in the future. Temozolomide33 can also
be used as an alternative drug (Supplementary Fig. 3d). The BEP
can also deliver multiple anticancer agents (DOX and TMZ) for
the combination therapy (Supplementary Fig. 3e). Although we
loaded two kinds of drugs in the BEP, the integrity of the device
was well maintained.
Since the adhesion force between the OST film and the brain
tissue is stronger than the mechanical strength of the brain
tissue34,35, the brain tissue is mechanically torn before the
detachment of the film from the brain surface. Therefore, the
effect of oxidization of starch on the adhesion strength was
indirectly tested on the bovine muscle instead of the brain tissue,
since the bovine muscle has higher mechanical strength than the
brain tissue. The shear adhesion test (Fig. 2b, inset) of OST
exhibited its strong adhesion to the muscle tissues (Fig. 1a, right)
than that of unmodified starch film (non-OST case, 0% in Fig. 2b)
due to imine conjugation (more oxidized units). The softness of
the BEP is optimized for its conformal adhesion to the convoluted
brain surface by changing the ratio of OST to glycerol
(Supplementary Fig. 4). The strong adhesion and softness enable
the conformal contact of the BEP at the tissue surface (Fig. 2c),
which allows local drug delivery (Fig. 2c, inset, white circle). The
diffusion length by the natural diffusion (Fig. 2c) is small.
However, it can be increased by additional mild-thermic
actuations.
The drug release from the patch at 37 °C is analyzed for
4 weeks in the phosphate-buffered saline (PBS; Fig. 2d) solution.
Compared with unmodified starch, OST shows more sustained
drug release, which prolongs the drug delivery duration. The
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burst drug release until day 1 (80% of DOX release) in the non-
OST case (control) corresponds to release of drugs physically
trapped in the polymer chain (Fig. 2a, yellow circle). The
suppressed burst release at the early stage (25% DOX until day 1)
and the sustained release until later periods (~50% until 4 weeks)
can be achieved in OST due to chemical conjugation (i.e.,
hydrolysis) of drug molecules with polymer chains (Fig. 2a, red
circle)36.
When hydrophobic PLA is coated both on the top and bottom
side of the OST substrate, it suppresses the drug release to the
PBS solution dramatically (Fig. 2d, red). The selective coating of
PLA only on the top surface of the device where the device is
exposed to CSF can decrease the unintended drug leakage to
other regions (Supplementary Figs. 5, 6; in vitro and in vivo,
respectively), although perfect prevention of the drug diffusion to
the CSF cannot be achieved due to biodegradation. Meanwhile,
the bottom hydrophilic OST substrate enhances adhesion of the
BEP to the brain surface and decrease the unintended drug
diffusion to CSF (Fig. 2e). The DOX concentration in canine CSF
in 1 week after implantation was measured to be 11.9 ng/mL at
3.15 min by high-performance liquid chromatography (HPLC)
(Fig. 2f; inset shows HPLC data of DOX standard solutions). This
shows minimal DOX leakage to CSF, which is important to
prevent drug waste and potential side effects37.
Fabricating the implant with materials that hydrolyze into
components of human body (Fig. 1b)24 makes the retrieval
surgery unecessary21,38,39 and reduces risks of potential side
effects of chronic neural implants15,16. Each component of the
BEP is converted into biocompatible metabolites. For example, it
takes 2 weeks for degradation of the wireless heater (Supplemen-
tary Fig. 7a, in vitro degradation; and Supplementary Fig. 7b,
in vivo degradation), regardless of the mild-thermic condition
(Supplementary Fig. 7c). The biodegradability of the overall
device (BEP) was tested in vivo (Fig. 2g). The BEP implanted in
canine brain dissolves within 10 weeks without any debris and
clinical side effects (Fig. 2g). This 10-week-period corresponds to
the entire duration of drug release in vivo.
In order to examine biocompatibility, the BEPs were implanted
on the surface of the surgical cavity made by the brain surgery in
BALB/c nude mice (Supplementary Fig. 8). The distribution of
astrocytes and microglia near the surgical cavity was observed in
both the sham (Fig. 2h, i, red) and BEP implantation (Fig. 2h, i,
blue) group at various time points (1 day, 2 weeks, 4 weeks, and
6 weeks). No significant increase of the migrated astrocytes and
microglia was observed after 2 weeks, and the differences of the
migrated astrocytes and microglia between the sham group and
the BEP group were not significant overall time periods. The
results suggest that the BEP did not induce the significant
immune response.
The implantation of the BEP to animals and its mild-thermic
actuation in vivo did not affect mouse brain functions. We
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Oxidized starch for intracranial DDS
Fig. 1 Materials, device design, and wireless actuation of the bioresorbable electronic patch (BEP). a Schematic illustration of the BEP (left) and the
molecular structure of drug-containing oxidized starch (OST) (right). b Schematic illustration of the BEP and its constituent materials (left), and their
biodegradation into hydrolyzed products (right). c Image of the BEP, which includes a bioresorbable wireless heater and a temperature sensor on an
oxidized starch (OST) patch containing doxorubicin (DOX). d Image of the sterilized BEP before implantation. e Images of brain craniotomy in the canine
model before (left) and after (right) BEP implantation. f Schematic illustration of localized and penetrative drug delivery to deep GBM tissues by the BEP
with wireless mild-thermic actuation
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The behavior was evaluated by the rotarod test (Supplementary
Fig. 9a, b). The intracranial electroencephalogram was also
monitored and analyzed (Supplementary Fig. 9c). According to
the mouse tests, no neurological deficits and abnormal behaviors
were observed.
The biocompatibility of the BEP was also tested in a large
animal (canine model). The BEP contains MRI contrast agents,
ferrimagnetic iron oxide nanocubes40 (Supplementary Fig. 10),
and thus its bioresorption and shape change in brain can be
monitored by MRI in vivo (Supplementary Fig. 11). The MR
images at different time points showed that the conformal contact
of the BEP to the brain surface was maintained during its
degradation. Compared with its initial state, the patch volume
decreased significantly after 9 weeks due to its bioresorption
(Supplementary Fig. 12a). Also, the intracranial implantation of
the BEP to canine brain did not exhibit any unexpected side
effects including brain swelling (Supplementary Fig. 11). The
brain tissue reaction to the BEP was evaluated by immunochem-
ical staining using hematoxylin and eosin (H&E) and macrophage
antibody in 1 week and 10 weeks after implantation. Any
significant inflammatory responses or physiological complica-
tions were not observed (Supplementary Fig. 12b). The longer-
term studies to observe the effect of hydrolyzed materials in vivo
are needed in the future.
Wireless mild-thermic actuation for accelerated drug delivery.
The acceleration of drug release by wireless mild-thermic actua-
tion (Fig. 3a) was characterized. The RF magnetic field applied by
an external coil triggers eddy current and joule heating in the
heater of the implanted BEP (Fig. 3b), resulting in the increased
temperature of the BEP and surrounding brain tissues. Key
parameters of the heater design are the diameter and thickness of
the round-shaped heater while the transmission coil current and
coil-to-heater distance can be varied to optimize the heat gen-
eration. The hole array in the wireless heater is helpful for facile
fabrication (transfer printing) of the device but slightly affects the
heat generation (Supplementary Fig. 13a, b). The temperature
change under the various coil-to-heater distances in the heater
(Fig. 3c) of different diameters and under the various coil-
currents in 12 mm diameter heater (Fig. 3c, inset) were measured
using our instrument to set the temperature change. Under dif-
ferent conditions, the calibration curve that shows the tempera-
ture increase as a function of the magnetic field (Supplementary
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Fig. 2 Materials, device characterization, and biocompatibiltiy. a Illustration of the trapped and conjugated DOX to the OST polymer chain. b Shear stress
for detachment of the OST film with the indicated level of oxidized units from the bovine muscle tissue. Inset shows a schematic illustration of the shear
stress measurement. Each experiment was repeated at least three times and error bars represent the standard error of the mean value. c Optical
microscope image (gray) overlapped by the fluorescence microscope image (red) at the brain-BEP interface. Image of a canine brain after diffusion of DOX
from the BEP (inset). d Cumulative release of DOX from unmodified starch (black), OST (blue), and PLA-encapsulated OST (red) in 37 °C phosphate-
buffered saline (PBS) solution for 4 weeks. e Illustration of the flexible bifacial patch conformally adhered on the brain cavity surface. f Measurement of
DOX concentration (dotted circle) in cerebrospinal fluid (CSF) after 1 week from implantation by HPLC. Inset shows HPLC measurement of standard DOX
solutions. g Optical camera image during the intracranial BEP implantation surgery (left) and at 10 weeks after implantation (right). Quantification of the
immunohistochemistry using BALB/c nude mice at different time points for the sham (red) and BEP implantation (blue) group (n= 7–8 for each group and
time): h for GFAP and i for Iba-1. (NS; p > 0.05 by paired t-test). Line: median box: 25th–75th percentiles, Whisker: min to max, *p < 0.05 by Man–Whitney
U-test with Bonferroni correction
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can be used to optimize the amount of heating. Also, the
dimension of the heaters (thickness and diameter) can be
decreased or the coil-to-heater distance can be increased further
by controlling the instrumental parameters such as the RF fre-
quency (Supplementary Fig. 13e, f). More details are described in
Supplementary Methods 1.1.
The amount of the drug release can be increased by mild-
thermic actuation at 42 °C (ΔT= 5 °C; Fig. 3d). The concentra-
tion gradient of DOX delivered into human GBM tissues (U87-
MG) with and without mild-thermic actuation was quantified in
an immune-deficient mouse in vivo by integrating equidistant
fluorescent signal counts. The natural diffusion of DOX (Fig. 3e)
is similar to the natural diffusion of carmustine41,42, and the
mild-thermic actuation dramatically enhances drug diffusion
(Fig. 3f, g). The actuation condition of ΔT= 5 °C (30 min of 2
pulses) results in death of deep cancer cells, which is shown in the
cross-sectional tissue staining image by terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) assay (Fig. 3h). The
drug delivery based on mild-thermic actuation over the longer
period of time (42 °C, 2 days, ex vivo) results in the enhanced
drug delivery depth (~11 mm, Supplementary Figs. 14 and 15a),
where the drug concentration is over CC50 of the tumor cell
(0.15 µg/mL; Supplementary Fig. 15b). This increased drug
penetration is due to increased cell membrane permeability43 at
increased temperature. The U87-MG cell is exposed to the drug
solution (DOX of 0.2 μg/mL) at 37 °C and 42 °C for 1 h, and the
number of nuclei stained by DOX is measured to compare drug
diffusion. The three-times higher drug uptake is observed at the
higher temperature (Fig. 3i and Supplementary Fig. 16).
The appropriate level of mild-thermic actuation promotes the
drug diffusion while minimizing the thermal damage to
surrounding brain tissues44, but excessive hyperthermia may
cause apoptosis45 of normal brain tissues. Thermal damage to the
brain tissue is analyzed by detecting expression of apoptosis
inhibitors with survivin (Fig. 3j and Supplementary Fig. 17). The
temperature increase of 5 °C for 30 min induced minimal
apoptosis, while the temperature increase of 10 or 15 °C caused
significant cell death (Fig. 3j). Numerical simulations (Fig. 3k,
Supplementary Fig. 18 and Supplementary Table 3) also
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Fig. 3 Wireless mild-thermic drug delivery. a Image of radio frequency (RF) wireless mild-thermic actuation in the canine GBM model. b Schematic
illustration of implanted BEPs and images of the mild-thermic actuation: optical (left) and infrared camera images before (middle) and during (right) the
wireless mild-thermic actuation. c Experimentally measured temperature change of the BEP by wireless heating depending on the coil-to-heater distance.
The inset shows the temperature change depending on the induced current. d Cumulative release of DOX from OST in PBS at 37 °C (blue) and 42 °C
(orange) for 4 weeks. e In vivo measurement of the DOX concentration at the indicated time points after implantation of the BEP without mild-thermic
actuation. f In vivo measurement of the DOX concentration at 15 h after implantation of the BEP with the pulsed mild-thermic actuation; control (black; no
pulse), 1 pulse (red), or 4 pulses (blue). g Fluorescence microscope images after 15 h implantation, which show DOX diffusion from the BEP into U87-MG
tumor tissues in the mouse model in vivo without (left) and with (right) the mild-thermic actuation. h Terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) assay of U87-MG tumor tissues without (left) and with (right) the mild-thermic actuation. i Proportion of DOX-stained cells after
exposure to the DOX solution for 1 h at 37 and 42 °C, measured by flow cytometry. Each experiment was repeated at least four times and error bars
represent the standard error of the mean value. j Effect of elevated temperatures on U87-MG tumor tissues, observed by survivin expression. k Contour
plot of the temperature distribution during the mild-thermic actuation. l Simulated temperature profile from the BEP surface into the brain under various
heater temperatures. The shadowed part represents the temperature that can be tolerated by the brain tissue
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under ΔT= 5 °C, which is consistent with experiments (Fig. 3j).
Heat is dissipated by blood flow at distal regions (Fig. 3k). The
absence or presence of skull does not cause differences on
temperature distribution according to 3D modeling (Supplemen-
tary Fig. 19 and Supplementary Table 4). The details of thermal
modeling are described in Supplementary Methods 1.2. Although
we tried to maintain the target temperature to be stable as shown
in Fig. 3b experiments and Fig. 3k simulations, it is true that
temperature fluctuations happen under pulsed wireless thermal
actuations in vivo. More reliable and elaborate heating protocols
should be developed through large scale in vivo animal
experiments in the future.
The optimal coil-to-heater distance at a given heater radius, in
which temperature is below 42 °C, can be estimated through
simulations (Fig. 3l). The drug diffusion coefficient increases
significantly by wireless mild-thermic actuation of ΔT= 5 °C,
consistent with previous reports (Supplementary Fig. 18a43,46).
For experimental validation of the optimal distance, temperature
increase by mild-thermic actuation is estimated by either an IR
camera or a wireless temperature sensor of the BEP (Supple-
mentary Fig. 20 and Supplementary Methods 1.3). The optimum
actuation condition is adopted to the therapy protocol.
Evaluation of therapeutic efficacy in the mouse and canine
GBMmodel. We evaluated therapeutic efficacy of the BEP in vivo
by using the human xenograft GBM model with immune-
deficient mice (BALB/c nude mice). Human GBM cells (U87-
MG) were cultured and subcutaneously implanted near the thigh
region of 6-week-old nude mice (n= 33). Tumor was grown and
resected similar to the standard protocol of human brain tumor47
therapy, and then the BEP of ~14 mm diameter was implanted.
Detailed surgical procedures are provided in Supplementary
Methods 1.4 and Supplementary Fig. 21. The protocol for the
therapy is presented in Fig. 4a. The procedure starts from the
tumor resection. Further studies for the nonresectable tumor
cases are also needed in the future.
Mice were divided into five groups: each treated with (1)
intravenous injection of DOX (IV group, Supplementary Fig. 22a);
(2) implantation of the BEP without DOX but with mild-thermic
actuation (Heating group; Supplementary Fig. 22b); (3) implanta-
tion of the BEP with DOX but without heating (OST group;
Supplementary Fig. 22c); (4) implantation of the custom-made
control wafer of which the composition is same as the Gliadel
wafer (194.4 mg poly[bis(p-carboxyphenoxy)propane] anhydride
and sebacic acid containing 7.7 mg carmustine) (control wafer
group; Fig. 4b); and (5) implantation of the BEP with DOX and
with mild-thermic actuation (OST+Heating group; Fig. 4c). The
DOX concentration in the BEP is 0.69 mg/BEP. The Heating and
OST+Heating group received wireless mild-thermic treatment
for 2 weeks following the therapy protocol (Fig. 4a).
The IV and Heating group exhibited poor prognoses, while the
OST and control wafer group showed meaningful suppression of
tumor recurrence (Supplementary Table 1). In particular, the
OST+Heating group exhibited significantly reduced tumor
volume among all groups, even compared with the control wafer
group (p= 0.0048) as shown in Fig. 4d and Supplementary
Table 1. It also leads to the dramatic increase in the survival rate
among all groups, even compared with the control wafer group
(p= 0.013) as shown in Fig. 4e and Supplementary Table 2. This
improvement in therapeutic efficacy shows combined benefits of
local drug delivery to the target region, long-lasting therapy due
to sustained drug release, and enhanced drug penetration by
mild-thermic actuation. Since the microenvironment in thigh is
different from that in brain, we additionally established a mouse
brain tumor model to prove efficacy of mild-thermic actuation in
brain (Supplementary Fig. 23a–e), which exhibited consistent
results with the subcutaneous tumor model results (Supplemen-
tary Fig. 23 and Supplementary Methods 1.5).
To obtain preclinical data of the BEP in large animals, a canine
GBM model was established. Since canine brain is much larger
than mouse brain, it allows a similar procedure with standard
human GBM surgery (Supplementary Fig. 24). Detailed proce-
dures are described in Supplementary Methods 1.6. Similar to the
conventional neurosurgery, the implanted GBM tissues were
partially removed by surgery while residual infiltrative tumor
tissues remained in the surgical cavity (Fig. 4f). The BEP was
implanted to the cavity, and the surgical site was covered by
surgical glue and skin without skull. Supplementary Fig. 25 shows
that tissues near the cavity have little mechanical damages,
confirming the surgical process is successful. The tumor volume
continuously increased unless treated (Fig. 4g, left). When
wireless mild-thermic treatment (ΔT= 5 °C, 30 min; 2 pulses)
was applied by the BEP, however, tumor growth was suppressed
(Fig. 4g, right) by intracranial drug delivery (Fig. 4h).
To evaluate therapeutic effect of the BEP further, both the BEP
and a control wafer were implanted to the brain cavity with the
remaining brain tumor in two different mongrel dogs. The
treatment with the BEP and the control wafer for 2 days caused
apoptosis of tumor cells, which are confirmed by TUNEL assay
(Fig. 4i, j and Supplementary Fig. 26). Both cases showed
apoptosis of tumor cells within 2 mm from the cavity surface.
However, the BEP induced apoptosis of deeply invaded micro-
scopic tumor cells (Fig. 4i) at 5 mm (Fig. 4j, Magnified H&E
TUNEL images in Supplementary Fig. 26a, b), while the control
wafer could not treat tumor cells located over 2 mm depth from
the cavity surface (Supplementary Fig. 26c, d). More deeply seated
tumor cells could be treated by the BEP, since drug penetration
can be extended by mild-thermic actuation of the BEP.
Discussion
In conclusion, we have developed a flexible, sticky, and biode-
gradable wireless device using bioresorbable materials and elec-
tronics design. The device, together with an associated mild-
thermic drug delivery protocol, achieved enhanced therapeutic
efficacy in brain tumor treatment. The integrated device and
protocol offered wirelessly controlled, spatially focused, and
temporally extended delivery of antitumor agents up to deeply
located brain tumors. The BEP dramatically suppressed tumor
volume and enhanced survival rate in vivo. The fully bioresorb-
able nature of the BEP provided intracranial biocompatibility and
minimized potential side effects. The proposed material and
device technology represents an important step toward intracra-
nial treatment of brain tumors.
Methods
Fabrication of the BEP. A sacrificial layer of poly(methyl methacrylate) (PMMA;
A11, Microchem, USA) was spin coated (176 g, 30 s) onto a silicon wafer and cured
at 180 °C for 3 min. The diluted polyimide (PI) precursor solution (poly(pyr-
omellitic dianhydride-co-4,4′-oxydianiline), amic acid solution; Sigma Aldrich,
USA) was spin coated onto the substrate (176 g, 60 s) and cured at 250 °C for 2 h to
form a bottom PI layer. PI was diluted by mixing the same mass of the PI precursor
solution and 1-methyl-2-pyrrolidinone (Sigma Aldrich, USA). A ZnO thin film
(2 nm) was deposited by AC sputtering under an Ar atmosphere (5 mTorr, 30W)
as an adhesion layer. In sequence, 3 μm of magnesium was deposited using a
thermal evaporator. Then, AZ5214 photoresist (PR; Microchem, USA) was spin
coated and patterned. The magnesium was etched using a custom-made magne-
sium etchant (nitric acid:deionized water:ethylene glycol; 1:1:3) to pattern the
wireless heater and temperature sensor. The diluted PI precursor solution was
again spin coated onto the substrate (176 g, 60 s) and cured at 250 °C for 2 h to
form a top PI layer. Then, the top and bottom PI layers were patterned using
AZ4620 PR (Microchem, USA). The PI was etched by oxygen plasma using a
reactive-ion etcher (O2, 100 sccm, 0.1 Torr, 100W). After patterning the PI, the
sacrificial PMMA layer was undercut etched using acetone at 70 °C. The device,
delaminated from the substrate, was picked up using a polydimethylsiloxane
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(PDMS) stamp (Sylgard 184, A:B= 10:1). Then, the bottom PI layer was etched by
oxygen plasma. Separately, 3% (w/w) PLA or 8% (w/w) PLGA was spin coated on
top of the OST film several times. The patch was exposed to the vapor of boiling
chloroform to make the PLA or PLGA sticky prior to transferring the device from
the PDMS stamp to the OST film. After the transfer, the top PI layer was etched by
oxygen plasma. Finally, PLA and PLGA were spin coated several times for top
encapsulation to protect the magnesium-based electronic device. Before
implantation of the BEP, each device that was transferred onto the OST film was
cut to have a circular shape with the diameter of 14 mm.
Mild-thermic actuation procedure. The mild-thermic actuation was applied
under the anesthesia in both mouse and canine model without the skull but with
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Fig. 4 Therapeutic efficacy of the BEP in BALB/c nude mouse and canine brain tumor models. a Therapy protocol employed to investigate the BEP in both
mouse and canine model. b Representative axial T2-weighted MR images of the control wafer group, and c OST+Heating group at the indicated time
points after surgery in the mouse model. d Time dependent mean tumor volumes of the indicated groups (left) and box-and-whisker plots of tumor
volumes at 26 days after surgery (right). n= 6, 7, 6, 7, 6 for IV, Heating, OST, OST+Heating, and control wafer group, respectively in the mouse model.
Line: median Box: 25th–75th percentiles, Whisker: min to max, *p < 0.05, **p < 0.01 by Man–Whitney U-test with Bonferroni correction. e Kaplan–Meier
survival rate plots of the indicated treatment group in the mouse model, *p < 0.05 by log-rank test with Bonferroni correction. f Histology images of tissues
near the J3T-1 implantation site stained with H&E in the canine model. g Coronal T2- (top) and contrast-enhanced T1-weighted MR images of the tumor
without (left) and with (right) the BEP treatment in the canine model. h Fluorescence images of DOX diffused from the BEP into the J3T-1 tissue in the
canine model in vivo without (left) and with the mild-thermic actuation in the canine model. i TUNEL assay of the BEP treatment case after 2 days from the
implantation (left) and its magnified view (right) in the canine model. j TUNEL assay of the control wafer treatment case after 2 days from the implantation
(left) and its magnified view (right) in the canine model
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pulse for two times every day in the mouse model, and 30 min pulse for two times
every 2 days in the canine model to prevent anesthetic death.
Histology. Tissues were fixed in 10% formalin, incubated in graded ethanol,
embedded in paraffin, and cut into 4-µm-thick sections. The histological analyses
were performed with H&E staining for basic morphological evaluation and TUNEL
(terminal deoxynucleotidyl transferase dUTP nick end labeling) staining for
apoptotic cell detection. For immunohistochemistry (IHC), all tissue sections were
deparaffinized in xylene and hydrated by immersion in a graded ethanol series.
Antigen retrieval was performed in a microwave by placing the sections in epitope
retrieval solution (0.01 M citrate buffer, pH 6.0) for 20 min; endogenous peroxidase
was inhibited by immersing the sections in 0.3% hydrogen peroxide for 10 min.
The sections were then incubated with a primary mouse monoclonal antibody to
macrophage (ThermoFisher Scientific, USA, MAC387, dilution 1:200) for inflam-
matory macrophages in a canine model or a rabbit monoclonal antibody to sur-
vivin (Cell Signaling, USA, #2808, dilution 1:300) in Dako REAL antibody diluent
(Dako, USA) for a mouse model. The IHC staining of GFAP and Iba-1 for bio-
compatibility test was performed with the rabbit monoclonal anti-GFAP (Abcam,
USA, ab7260, dilution 1:2000) and anti-Iba-1 (Wako Chemicals, USA, 019–19741,
dilution 1:3000) using the Dako Autostainer Link 48 system according to recom-
mended protocols. Two regions of interest from each slide were acquired and all
images were analyzed using Image J.
Statistics. The final tumor volume for all mice in each group was compared and
evaluated by using the Mann–Whitney U-test. The p value for the individual test
was multiplied by the number of comparison made (Bonferroni correction). The
log-rank test was used to compare the survival plot of each group. The p value for
the individual test was also multiplied by the number of comparison made
(Bonferroni correction). The paired t-test was used to compare the rotarod
retention time of two groups. The paired t-test was used to compare the quanti-
fication results of immunohistochemistry.
Ethical approval. This study was approved by our Institutional Animal Care and
Use Committee (IACUC; No. 14-0156-C2A3) and was performed in accordance
with our IACUC guidelines and with the National Institute of Health Guide for the
Care and Use of Laboratory Animals.
Cell lines. The human GBM cell line (U87-MG) was obtained from the American
Type Culture Collection (Rockville, USA, HTB-14) and maintained in RPMI
medium with 10% fetal bovine serum (FBS) at 37 °C. All cell lines were routinely
tested to exclude infection with mycoplasma and reauthenticated using micro-
satellite profiling immediately prior to manuscript submission. The canine glio-
blastoma cell line (J3T-1), which was derived from the parental canine glioma cell
line (J3T), was provided by T.I, Okayama University Graduate School of Medicine,
Dentistry, and Pharmaceutical Sciences (Japan) after obtaining research ethics
approval, and maintained in the Roswell Park Memorial Institute (RPMI) medium
with 10% FBS at 37 °C48–50. For this study, the cell line used was routinely tested to
exclude infection with mycoplasma.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The datasets generated during and/or analysed during the current study are available
from the corresponding author upon reasonable request.
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